PYC 4.76% 10.0¢ pyc therapeutics limited

Hi Heskumdai,The Chairman's Update in March 2013 was given the...

  1. 1,516 Posts.
    lightbulb Created with Sketch. 1899
    Hi Heskumdai,

    The Chairman's Update in March 2013 was given the thumbs down by many anxious shareholders who were looking for positive direction on existing collaborations and new deals. In hindsight, however, it possibly signalled more important guidance in relation to technological enhancements to the platform. We have guidance from the CFO that data on the Endosomal Escape Trap technology will be presented end of month. It is the first of four key technology milestones which were outlined in the Update.

    Until the data is presented we are somewhat flummoxed as to its significance! Putting caution aside, however, it may demonstrate that the science is evolving rather quickly. Is it evolving too quickly to commercialise? I think the answer could be Yes, albeit as you say, in an ironic sort of way.

    The recent developments in the technology require a new approach to commercialising access to the libraries. Precisely why Stecyk, from Griffin Securities, talks about exploring a variety of strategic options including broad therapeutic discovery alliances. Instead of doing plain vanilla deals we now hear about strategic alliances and partnerships, and strategic opportunities with biotech's who own synergistic technology.

    I'm not sure if this helps or muddies the water.

    Wayne.
 
watchlist Created with Sketch. Add PYC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.